The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy
Open accessAbstract
BACKGROUND: Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical treatment has not been defined. METHODS: In a double-blind, randomized, controlled clinical trial, we compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children with newly diagnosed childhood absence epilepsy. Drug doses were incrementally increased until the child was free of seizures, the maximal allowable or highest tolerable dose was reached, or a criterion indicating treatment failure was met. The primary outcome was freedom from treatment failure after 16 weeks of therapy; the secondary outcome was attentional dysfunction. Differential drug effects were determined by means of pairwise comparisons. RESULTS: The 453 children who were randomly assigned to treatment with ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar with respect to their demographic characteristics. After 16 weeks of therapy, the freedom-from-failure rates for ethosuximide and valproic acid were similar (53% and 58%, respectively; odds ratio with valproic acid vs. ethosuximide, 1.26; 95% confidence interval [CI], 0.80 to 1.98; P=0.35) and were higher than the rate for lamotrigine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% CI, 1.65 to 4.28; odds ratio with valproic acid vs. lamotrigine, 3.34; 95% CI, 2.06 to 5.42; P<0.001 for both comparisons). There were no significant differences among the three drugs with regard to discontinuation because of adverse events. Attentional dysfunction was more common with valproic acid than with ethosuximide (in 49% of the children vs. 33%; odds ratio, 1.95; 95% CI, 1.12 to 3.41; P=0.03). CONCLUSIONS: Ethosuximide and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilepsy. Ethosuximide is associated with fewer adverse attentional effects. (ClinicalTrials.gov number, NCT00088452.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisconsin Card Sorting Test Manual – Revised and Expanded
Heaton, R. K., Chelune, C., Talley, J., Kay, G., & Curtiss, G. (1981) · Medical Entomology and Zoology · Cited by 2,987
Woodcock-Johnson III Tests of Achievement
(2012) · SpringerReference · doi:10.1007/springerreference_180722 · Cited by 1,566
Glauser, T., Ben‐Menachem, E., Bourgeois, B., Cnaan, A., Chadwick, D., Guerreiro, C., Kalviainen, R., Mattson, R., Perucca, E., & Tomson, T. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00585.x · Cited by 790
Self-citationThe Treatment of Epilepsy : Principles and Practice
Wyllie, E. (1997) · Cited by 706
Patsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00483-6 · Cited by 391
Design and analysis of group sequential tests based on the type I error spending rate function
KIM, K., & DEMETS, D. L. (1987) · Biometrika · doi:10.1093/biomet/74.1.149 · Cited by 295
Newly Diagnosed Unprovoked Epileptic Seizures: Presentation at Diagnosis in CAROLE Study
Jallon, P., Loiseau, P., Loiseau, J., & de l'Epilepsie), O. B. O. G. C. (. A. D. R. O. L. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.31400.x · Cited by 254
Lamictal (Lamotrigine) Monotherapy for Typical Absence Seizures in Children
Frank, L. M., Enlow, T., Holmes, G. L., Manasco, P., Concannon, S., Chen, C., Womble, G., & Casale, E. J. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00805.x · Cited by 218
Long-term Psychosocial Outcome in Typical Absence Epilepsy: Sometimes a Wolf in Sheeps' Clothing
Wirrell, E. C. (1997) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1997.02170390042008 · Cited by 214
Validation of a New Quality of Life Measure for Children with Epilepsy
Sabaz, M., Cairns, D. R., Lawson, J. A., Nheu, N., Bleasel, A. F., & Bye, A. M. E. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00240.x · Cited by 213
Treatment of Pediatric Epilepsy: Expert Opinion, 2005
Wheless, J. W., Clarke, D. F., & Carpenter, D. (2005) · Journal of Child Neurology · doi:10.1177/088307380502000101 · Cited by 198
Berg, A. T., Shinnar, S., Levy, S. R., Testa, F. M., Smith‐Rapaport, S., & Beckerman, B. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb04604.x · Cited by 155
Self-citationLoiseau, P., Duché, B., & Pédespan, J. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01060.x · Cited by 149
Initial Management of Epilepsy
French, J. A., & Pedley, T. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801738 · Cited by 129
Callaghan, N., O’Hare, J. A., O'Driscoll, D., O’Neill, B., & Daly, M. (1982) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1982.tb13703.x · Cited by 120
The outcome of absence epilepsy
Bouma, P. A. D., Westendorp, R. G. J., van Dijk, J. G., Peters, A. C. B., & Brouwer, O. F. (1996) · Neurology · doi:10.1212/wnl.47.3.802 · Cited by 82
Lamotrigine in typical absence epilepsy
Buoni, S., Grosso, S., & Fois, A. (1999) · Brain and Development · doi:10.1016/s0387-7604(99)00023-6 · Cited by 42
(2001) · Medical Entomology and Zoology
Cited by
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Moshé, S. L., Perucca, E., Ryvlin, P., & Tomson, T. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60456-6 · Cited by 905
Glauser, T., Ben‐Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kälviäinen, R., Mattson, R., French, J. A., Perucca, E., Tomson, T., et al. (2013) · Epilepsia · doi:10.1111/epi.12074 · Cited by 721
Self-citationModern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
The cognitive impact of antiepileptic drugs
Eddy, C. M., Rickards, H. E., & Cavanna, A. E. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611417920 · Cited by 404
Metadata
- Authors
- Glauser, T. A., Cnaan, A., Shinnar, S., Hirtz, D. G., Dlugos, D., Masur, D., Clark, P. O., Capparelli, E. V., & Adamson, P. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-04
- Volume
- 362
- Issue
- 9
- Pages
- 790-799
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2030113059
- Cited by
- 645
- References
- 19
- FWCI
- 32.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.